ArticleMetabolomics : Official journal of the Metabolomic Society2025
Metabolomic profiling of renal cyst fluid in advanced ADPKD: insights from dialysis and transplantation cohorts.
Article in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HILIC-MS/MS-based strategy for quantitative amino acid profiling in multiple biological matrices and its application in kidney disease samples.Analytical and bioanalytical chemistry · 2026Article
- Comparison Between the Human-Sourced Ellipsoid Method and Kidney Volumetry Using Artificial Intelligence in Polycystic Kidney Disease.Journal of personalized medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder characterized by progressive renal cyst formation, often leading to end-stage kidney disease (ESKD). In contrast to the urinary metabolome in ADPKD, the composition of renal cyst fluid remains largely unexplored.
methodsWe conducted a comprehensive metabolomic analysis of renal cyst fluid from 26 ADPKD patients (20 on dialysis, six with kidney transplants) using ¹H-NMR spectroscopy and liquid chromatography-mass spectrometry (LC-MS). Cysts were clustered based on metabolite profiles, and differences were analyzed across groups defined by renal function status (dialysis vs. transplant), cyst volume, and cyst fluid sodium concentrations.
resultsDialysis patients and transplant recipients differed significantly in their renal cyst fluid metabolomes. The former exhibited higher concentrations of myoinositol, creatinine, sucrose, τ-methylhistidine, trigonelline, and sarcosine, while the latter showed increased levels of leucine, isoleucine, valine and alanine. Remarkably, metabolites of the immunosuppressive prodrug mycophenolate mofetil were detected in renal cyst fluids after kidney transplantation. Despite intra- and interindividual variability, cyst fluid from the same patient displayed greater homogeneity. Interestingly, metabolomic profiles were not altered by cyst size.
conclusionThis first systematic metabolomic analysis of renal cyst fluid in advanced ADPKD reveals distinct metabolic signatures linked to renal function status. The data provides novel insights into the pathophysiology of ADPKD and highlight the potentials of renal cyst fluid metabolomics for identifying biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.